Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis

Mise à jour : Il y a 4 ans
Référence : NCT02289417

Femme et Homme

Extrait

The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in subjects with active Ulcerative Colitis (UC).


Critère d'inclusion

  • Ulcerative colitis